Ahmed A S M, Long M. and Donaldson D. (2000). Ascites and elevated serum CA 125 due to a pancreatic carcinoma. A diagnostic dilemma. J Royal Soc Health; 120(1), 47-51
2.
Ammon A., Eiffert H., Weber MH, Rummel J. and Niemann J. (1988). Tumour markers in dialysis-dependent renal failure: A comparison of the mucin-like carcinoma antigen, CA-15-3, CA 125, CA-19-9 and CEA antigens. Onkologie; 11(6), 260-262
3.
Arik N., Adam B., Akpolat T., Hasil K. and Tabak S. (1996). Serum tumour markers in renal failure. Int Urol Nephrol; 28(4), 601-604
4.
Bastani B. and Chu N. (1995). Serum CA 125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. Am J Nephrol; 15(6), 468-472
5.
Bergmann J.R., Bidart J.M., George M., Beaugrand M., Levy V.G. and Behoun C. (1987). Elevation of CA 125 in patients with benign and malignant ascites. Cancer, 59, 213-217
6.
Bischof P. (1993). What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol; 49(1-2), 93-98
7.
Cases A., Filella X., Molina R., Ballesta A.M., Lopez-Pedret J. and Revert L. (1991). Tumor markers in chronic renal failure and hemodialysis patients. Nephron; 57(2),183-186
8.
Filella X., Cases A., Molina R., Jo J., Bedini J.L., Revert L. and Ballesta A.M. (1990). Tumor markers in patients with chronic renal failure . Int J Biol Markers; 5(2), 85-88
9.
Kabawat S.E., Bast R.C. JR, Bhan A.K., Welch W.R., Knapp R.C. and Colvin R.B. (1983). Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol; 2(3), 275-285
10.
Kawabe T., Ishii M., Sugimoto M. and Tagawa H. (1987). Low serum CA125 concentration in chronic renal failure treated with continuous ambulatory peritoneal dialysis. Clin Chim Acta; 168(1), 113-114
11.
Lye W.C., Tambyah P., Leong S.O. and Lee E.J. (1994). Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial; 10, 109-111
12.
Menzin A.W., Kobrin S., Pollak E., Goodman D.B. and Rubin S.C. (1995). The effect of renal function on serum levels of CA 125. Gynecol Oncol; 58(3), 375-377
13.
Nguyen H.N. (1998). Extreme CA125 elevation from hepatitis C and ascites . Gynecol Oncol; 70(3), 441-442
14.
Odagiri E., Jibiki K., Takeda M., Sugimura H., Iwachika C., Abe Y., Kihara K., Kihara Y., Itou M., Nomura T., et al (1991). Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA-19-9 and CA-15-3 in uremic patients. Am J Nephrol; 11(5), 363-368
15.
Sevinc A., Buyukberber S., Sari R., Turk H.M. and Ates M. (2000a). Elevated serum CA 125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res; 20(2B), 1201-1203
16.
Sevinc A., Buyukberber S., Sari R., Kiroglu Y., Turk H.M. and Ates M. (2000b). Elevated serum CA 125 levels in patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol ; 77(2), 254-257
17.
Sevinc A., Buyukberber S. and Sari R. (2000c). Elevated serum CA 125 levels: Hepatitis or ascites ? Gynecol Oncol; 76(1), 141
18.
Zeferos N., Digenis G.E., Christophoraki M., Alexopoulos I., Kostakis A., Gyftaki H. and Moulopoulos S. (1991). Tumor markers in patients undergoing hemodialysis or kidney transplantation. Nephron; 59(4), 618-620
19.
Zeimet A.G., Marth C., Offner F.A., Obrist P., Uhl-Steidl M., Feichtinger H., Stadlmann S., Daxenbichler G. and Dapunt O. (1996). Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA 125. Gynecol Oncol; 62(3), 384-389
20.
Zuckerman E., Lanir A., Sabo E., Rosenvald-Zuckerman T., Matter I., Yeshurun D. and Eldar S. (1999). Cancer Antigen 125: A sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol; 94(6), 1613-1618
21.
Alper Sevinc, MD and Ramazan Sari , MD, Inonu University, School of Medicine, Department of Internal Medicine, Turgut Ozal Medical Centre, Malatya, TR-44069, Turkey; and Celalettin Camci , MD and Suleyman Buyukberber, MD, Gaziantep University, School of Medicine, Department of Medical Oncology, Gaziantep, Turkey
22.
Ahmed A S M, Long M. and Donaldson D. (2000). Ascites and elevated serum CA 125 due to a pancreatic carcinoma. A diagnostic dilemma. J Royal Soc Health; 120(1), 47-51
23.
Ammon A., Weber H.M., Wallner I., Marschner N., Droese M., Grone H.J., et al (1994). Expression of the tumour-associated glycoproteins MCA, CA 125 and BW 495/36-P in epithelial tumors of the kidney and urinary bladder. Int J Biol Markers; 9(4), 224-230
24.
Bast R.C. Jr, Knauf S., Epenetos A., Dhokia B., Daly L., Tanner M., Soper J., et al (1991). Coordinate elevation of serum markers in ovarian
25.
cancer but not in benign disease. Cancer68(8), 1758-1763
26.
D C., Bruno P., Cirillo D., Morgera R., Pellicano M. and Nappi C. (1997). Increased concentrations of renin, aldosterone and CA 125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulartion syndrome. Hum Reprod; 12(10), 2115-2117
27.
Jacobs I. and Bast R.C. Jr (1989). The CA 125 tumour associated antigen: a review of the literature. Human Reprod; 4(1), 1-12
28.
Jacobs I.J., Oram D.H. and Bast R.C. Jr (1992). Strategies for improving the specificity of screening for ovarian cancer with tumour-associated antigens CA 125, CA 15-3 and TAG 72. Obstet Gynaecol; 80, 396-399
29.
Nih (1995). Consensus Development Panel on ovarian cancer, ovarian cancer screening, treatment, and follow-up . JAMA; 273, 491-497
30.
Rubin J. and Rockey D.C. (1999). Cirrhotic ascites, ovarian carcinoma and CA 125 . South Med J; 92(2), 248-250
31.
Sakamoto K., Haga Y., Yoshimura R., Egami H. and Yokoya-Ma Y. (1987). Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125, and carcinoembryonic antigen in patients with diseases of the digestive system. Gut; 28, 323-329
32.
Sevinc A., Buyukberber S., Sari R., Turk H.M. and Ates M. (2000). Elevated serum CA 125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res; 20(2B), 1201-1203
33.
Udagawa Y., Aoki D., Ito K., Uejima T., Uemura M. and Nozawa S. (1998). Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT). Eur J Cancer34, 489-495Woolas R.P., Xu F.J., Jacobs I.J., Yu Y.H., Daly L., Berchuck A., Soper J.T., et al (1993). Elevation of multiple serum markers in patients with stage 1 ovarian cancer . J Nat Cancer Inst; 85(21), 1748-1751
34.
Ahmed Sekotory Mahmoud Ahmed, MB, BCh, MRCOG, Registrar in Obstetrics and Gynaecology, East Surrey Hospital, Redhill, Surrey, England; Matthew Long, MD, MRCOG, Consultant Obstetrician and Gynaecologist, East Surrey Hospital, Redhill, Surrey, England; and David Donaldson, MB, ChB, FRCP, FRCPath, Consultant Chemical Pathologist, East Surrey Hospital, Redhill, Surrey and Crawley Hospital, Crawley, West Sussex, England
